Chimeric antigen receptors and methods of use
Chimeric antigen receptors containing tumor necrosis factor receptor superfamily member transmembrane domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
1. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO: 8.
2. The method of claim 1 , wherein the cancer is a hematological cancer selected from the group consisting of leukemia, lymphoma, and multiple myeloma.
3. The method of claim 2 , wherein the leukemia is chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), or chronic myelogenous leukemia (CIVIL).
4. The method of claim 2 , wherein the lymphoma is mantle cell lymphoma, non-Hodgkin's lymphoma or Hodgkin's lymphoma.
5. The method of claim 1 , wherein the cancer is selected from the group consisting of oral and pharynx cancer, a hematological cancer, a digestive system cancer, a respiratory system cancer, a bone and joint cancer, a soft tissue cancer, a skin cancer, a pediatric tumor, a tumor of the central nervous system, a cancer of the breast, a cancer of the genital system, a cancer of the urinary system, a cancer of the eye and orbit, a cancer of the endocrine system, a cancer of the brain and other nervous system, and a combination thereof.
6. The method of claim 1 , wherein the nucleic acid sequence that encodes the CAR comprises the nucleic acid sequence of SEQ ID NO: 7, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof.
7. The method of claim 1 , wherein the nucleic acid sequence that encodes the CAR comprises the nucleic acid sequence of SEQ ID NO: 40, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof.
8. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO: 10.
9. The method of claim 8 , wherein the nucleic acid sequence that encodes the CAR comprises the nucleic acid sequence of SEQ ID NO: 9, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof.
10. The method of claim 8 , wherein the cancer is a hematological cancer selected from the group consisting of leukemia, lymphoma, and multiple myeloma.
11. The method of claim 10 , wherein the leukemia is chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), or chronic myelogenous leukemia (CML).
12. The method of claim 10 , wherein the lymphoma is mantle cell lymphoma, non-Hodgkin's lymphoma or Hodgkin's lymphoma.
13. The method of claim 8 , wherein the cancer is selected from the group consisting of oral and pharynx cancer, a hematological cancer, a digestive system cancer, a respiratory system cancer, a bone and joint cancer, a soft tissue cancer, a skin cancer, a pediatric tumor, a tumor of the central nervous system, a cancer of the breast, a cancer of the genital system, a cancer of the urinary system, a cancer of the eye and orbit, a cancer of the endocrine system, a cancer of the brain and other nervous system, and a combination thereof.
14. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO: 36.
15. The method of claim 14 , wherein the nucleic acid sequence that encodes the CAR comprises the nucleic acid sequence of SEQ ID NO: 35, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof.
16. The method of claim 14 , wherein the cancer is a hematological cancer selected from the group consisting of leukemia, lymphoma, and multiple myeloma.
17. The method of claim 16 , wherein the leukemia is chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), or chronic myelogenous leukemia (CML).
18. The method of claim 16 , wherein the lymphoma is mantle cell lymphoma, non-Hodgkin's lymphoma or Hodgkin's lymphoma.
19. The method of claim 14 , wherein the cancer is selected from the group consisting of oral and pharynx cancer, a hematological cancer, a digestive system cancer, a respiratory system cancer, a bone and joint cancer, a soft tissue cancer, a skin cancer, a pediatric tumor, a tumor of the central nervous system, a cancer of the breast, a cancer of the genital system, a cancer of the urinary system, a cancer of the eye and orbit, a cancer of the endocrine system, a cancer of the brain and other nervous system, and a combination thereof.